| 國立成功大學 |
2023 |
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
|
Xie, E.;Yeo, Yeo Y.H.;Scheiner, B.;Zhang, Y.;Hiraoka, A.;Tantai, X.;Fessas, P.;De, Castro T.;D'Alessio, Alessio A.;Fulgenzi, C.A.M.;Xu, S.;Tsai, H.-M.;Kambhampati, S.;Wang, Wang W.;Keenan, B.P.;Gao, X.;Xing, Z.;Pinter, M.;Lin, Y.-J.;Guo, Z.;Vogel, A.;Tanaka, Tanaka T.;Kuo, H.-Y.;Kelley, R.K.;Kudo, M.;Yang, J.D.;Pinato, D.J.;Ji, F. |
| 臺大學術典藏 |
2022-06-10T06:10:51Z |
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
|
Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN; Youkstetter J.; Hazra S.; Sen S.; Cheng A.-L.; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
|
Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I. |
| 國立成功大學 |
2022 |
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
|
Zhu, A.X.;Dayyani, F.;Yen, C.-J.;Ren, Z.;Bai, Y.;Meng, Z.;Pan, H.;Dillon, P.;Mhatre, S.K.;Gaillard, V.E.;Hernandez, S.;Kelley, R.K.;Sangro, B. |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
|
Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
|
Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
|
Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
|
Javle M.;Lowery M.;Shroff R.T.;Weiss K.H.;Springfeld C.;Borad M.J.;Ramanathan R.K.;Goyal L.;Sadeghi S.;Macarulla T.;El-Khoueiry A.;Kelley R.K.;Borbath I.;Choo S.P.;Oh D.-Y.;Philip P.A.;Chen L.-T.;Reungwetwattana T.;Van Cutsem E.;Kun-Huei Yeh;Ciombor K.;Finn R.S.;Patel A.;Sen S.;Porter D.;Isaacs R.;Zhu A.X.;Abou-Alfa G.K.;Bekaii-Saab T.; Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
|
Abou-Alfa G.K.;Yau T;Ryoo B.-Y;Knox J;Brown J;Kelley R.K;Chao T.-Y;Choi H.J;Freilich B;Modiano M;Yoon J.-H;Chia-Chi Lin;Yong W.P;Lim H.Y;El Dika I; El Dika I; Lim H.Y; Yong W.P; Chia-Chi Lin; Yoon J.-H; Modiano M; Freilich B; Choi H.J; Chao T.-Y; Kelley R.K; Brown J; Knox J; Ryoo B.-Y; Yau T; Abou-Alfa G.K. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
|
Abou-Alfa G.K.;Yau T;Ryoo B.-Y;Knox J;Brown J;Kelley R.K;Chao T.-Y;Choi H.J;Freilich B;Modiano M;Yoon J.-H;Chia-Chi Lin;Yong W.P;Lim H.Y;El Dika I; El Dika I; Lim H.Y; Yong W.P; Chia-Chi Lin; Yoon J.-H; Modiano M; Freilich B; Choi H.J; Chao T.-Y; Kelley R.K; Brown J; Knox J; Ryoo B.-Y; Yau T; Abou-Alfa G.K. |
| 國立成功大學 |
2018 |
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
|
Javle, M.;Lowery, M.;Shroff, R.T.;Weiss, K.H.;Springfeld, C.;Borad, M.J.;Ramanathan, Ramanathan R.K.;Goyal, L.;Sadeghi, Sadeghi S.;Macarulla, T.;El-Khoueiry, A.;Kelley, R.K.;Borbath, I.;Choo, S.P.;Oh, D.-Y.;Philip, Philip P.A.;Chen, L.-T.;Reungwetwattana, T.;Van, Cutsem E.;Yeh, K.-H.;Ciombor, K.;Finn, R.S.;Patel, A.;Sen, Sen S.;Porter, D.;Isaacs, R.;Zhu, A.X.;Abou-Alfa, G.K.;Bekaii-Saab, T. |
